Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Senate Rx Import Bill Will Add Stronger Anti-Counterfeit Provisions In 2005

This article was originally published in The Pink Sheet Daily

Executive Summary

When Health Committee Chairman Judd Gregg (R-N.H.) reintroduces his drug importation bill, it will include requirements for full drug "pedigrees" on imported drugs. Legislation could also set up requirements for pedigrees on domestic drugs.

You may also be interested in...



Sen. Gregg Will Retain Influence Over Medicare Following Move To Budget Cmte.

Health Committee Chairman Gregg expects to influence the fiscal direction of Medicare through the reconciliation process or “in some other way.” He intends to remain a member of the Health Committee and anticipates that Sen. Michael Enzi will become the next chairman.

Sen. Gregg Will Retain Influence Over Medicare Following Move To Budget Cmte.

Health Committee Chairman Gregg expects to influence the fiscal direction of Medicare through the reconciliation process or “in some other way.” He intends to remain a member of the Health Committee and anticipates that Sen. Michael Enzi will become the next chairman.

House Wary Of Reopening Medicare Rx Legislation, Staffer Says

The House will focus on helping CMS implement the bill, House Republican staffer Canfield says. Reopening the bill to make changes could result in “mischief,” but a technical corrections bill may be needed, she notes.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS058308

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel